[Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study].
To study indexes of efficacy, safety and compliance for different ASA forms (Aspirin-Cardio, Cardiomagnyl, Thrombo ASS) used in stable IHD. An open, cross-sectional study compared three groups of patients consisting of 200 patients each who had stable IHD and a high risk of gastrointestinal disorders and who received a long-term antiaggregant monotherapy with one of ASA drugs (group 1, Aspirin Cardio; group 2, Thrombo ASS; group 3, Cardiomagnyl). Efficacy, safety and compliance with the treatment were evaluated using standard tests and analogue scales; dyspepsia symptoms were evaluated using a special, additionally developed questionnaire. The Aspirin-Cardio treatment reduced the mean score of GI symptom severity from the questionnaire (1.4-1.6 times, р=0.001), requirement for proton pump inhibitors (р=0.002) and endoscopy during the ASA treatment the mean score of GI symptom questionnaire >3 predicted non-compliance or insufficient compliance with a diagnostic sensitivity of 58.9 % and specificity of 56.3 % (р=0.002), which makes this value a threshold for considering a modification of the treatment. Aspirin-Cardio is characterized by better safety in respect of GI symptoms and better compliance with the treatment during long-term prophylactic therapy. The proposed questionnaire for evaluation of GI symptoms can be used for specifying indications and modifying the treatment tactics.